TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07869836: BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-b

Sponsor: SystImmune Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 520 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07869836 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07869836 Rescue Dossier →